Meeting
2022 ASCO Annual Meeting
Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVEC trial.
Authors
Maartje W. Rohaan
Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands
Maartje W. Rohaan , Lisanne P. Zijlker , Emma H.A. Stahlie , Viola Franke , Sofie Wilgenhof , Vincent van der Noort , Alexander Christopher Jonathan Van Akkooi , John B. A. G. Haanen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT04330430
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9607)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9607
Abstract #
TPS9607
Poster Bd #
192a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.
First Author: Lisanne P. Zijlker
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2023 ASCO Annual Meeting
The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma.
First Author: Faisal Fa'ak
Poster
2021 Gastrointestinal Cancers Symposium
FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)—The short-term results of cohort A and B.
First Author: Shun Yamamoto